NASDAQ:LSTA Lisata Therapeutics Q4 2025 Earnings Report $3.45 0.00 (0.00%) As of 01:23 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lisata Therapeutics EPS ResultsActual EPS-$0.33Consensus EPS -$0.74Beat/MissBeat by +$0.41One Year Ago EPSN/ALisata Therapeutics Revenue ResultsActual Revenue$0.10 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALisata Therapeutics Announcement DetailsQuarterQ4 2025Date3/12/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsLisata Therapeutics' next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules. Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Lisata Therapeutics Earnings HeadlinesLisata Therapeutics (NASDAQ:LSTA) Stock Price Up 4.3% - Here's WhyJune 11, 2026 | americanbankingnews.comLisata Therapeutics, Inc.: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.June 10, 2026 | finanznachrichten.deSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $1.75 trillion valuation and 266 times earnings, you're buying in at the most expensive IPO in history - right when institutions who got in at $800 billion need someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure Colossus can't run without - and it's still trading at a fraction of its value.June 16 at 1:00 AM | Behind the Markets (Ad)Lisata Therapeutics agrees to Kuva Labs buyout at $4 per shareJune 10, 2026 | proactiveinvestors.comLisata Therapeutics Announces Tender Offer from Kuva Acquisition Corp at $4.00 per Share Plus Contingent Value RightsJune 10, 2026 | quiverquant.comQLisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.June 10, 2026 | globenewswire.comSee More Lisata Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lisata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lisata Therapeutics and other key companies, straight to your email. Email Address About Lisata TherapeuticsLisata Therapeutics (NASDAQ:LSTA) (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches. Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies. To advance its programs, the company collaborates with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe. Headquartered in the United States, Lisata Therapeutics is governed by a leadership team with experience in biotechnology research, clinical operations and regulatory affairs. The company’s board and scientific advisors bring expertise in immunology, drug development and commercial strategy to support its mission of addressing unmet medical needs.View Lisata Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Lennar Finally Turning the Corner After Its Housing Slump?Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?This Golden Cross Could Send Urban Outfitters to New Highs3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Goldman’s S&P 500 Target Looks More Reachable After the Latest Rally Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
